Scarica l'app Stockscreener
2.06
1.48%
0.03
Dopo l'orario di chiusura:
2.05
-0.01
-0.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$2.03
Aprire:
$2.03
Volume 24 ore:
1.10M
Relative Volume:
0.82
Capitalizzazione di mercato:
$375.00M
Reddito:
-
Utile/perdita netta:
$-236.93M
Rapporto P/E:
-1.42
EPS:
-1.4507
Flusso di cassa netto:
$-206.44M
1 W Prestazione:
-5.50%
1M Prestazione:
-31.33%
6M Prestazione:
+11.96%
1 anno Prestazione:
+214.02%
Intervallo 1D:
$1.98
$2.10
Intervallo di 1 settimana:
$1.98
$2.205
Portata 52W:
$0.611
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.06 | 369.54M | 0 | -236.93M | -206.44M | -1.4507 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode - Insider Monkey
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Neumora Therapeutics (NMRA) price target increased by 19.25% to 9.33 - MSN
Rally Mode: Is Neumora Therapeutics Inc forming a breakout patternInflation Watch & Growth Oriented Trade Recommendations - baoquankhu1.vn
Short Squeeze: Does Neumora Therapeutics Inc stock have upside surprise potentialEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim - The Globe and Mail
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead - TipRanks
Loss Report: Will Neumora Therapeutics Inc benefit from geopolitical trendsQuarterly Market Summary & Trade Opportunity Analysis - baoquankhu1.vn
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $6 to $18 - Moomoo
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access - TipRanks
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% By Investing.com - Investing.com India
Guggenheim reiterates Neumora stock rating on pipeline progress By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Neumora Therapeutic (NMRA.US) will release its earnings report before the market opens on March 30. - Moomoo
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics 2025 Financial Update - AlphaStreet
Neumora Therapeutics Reports Strong 2025 Financials and Clinical Pipeline Progress Including NMRA-511 Alzheimer’s Agitation Data and KOASTAL-2/3 Enrollment 123 - Minichart
Stifel reiterates Neumora Therapeutics stock Hold rating at $3 By Investing.com - ca.investing.com
Neumora Therapeutics Sees Unusually Large Options Volume (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Neumora 2025 10-K Report: Precision Neuroscience, Intellectual Property, and Business Overview - Minichart
Earnings call transcript: Neumora Therapeutics beats Q4 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Neumora Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Neumora Therapeutics beats Q4 2025 EPS forecast, stock dips - Investing.com
Neumora Therapeutics Q4 Earnings Call Highlights - MarketBeat
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% - Investing.com Australia
Neumora Therapeutics, Inc. (NMRA) Q4 FY2025 earnings call transcript - Yahoo Finance
Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Neumora (NASDAQ: NMRA) maps key 2026–27 milestones for depression, Alzheimer’s and obesity drugs - Stock Titan
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Neumora (NMRA) posts 2025 loss, advances CNS pipeline with key 2026–27 milestones - Stock Titan
Neumora Therapeutics (NMRA) price target decreased by 16.15% to 7.82 - MSN
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):